A Web-based Calculator Predicts Heterogeneous Frailty Trajectories

NCT ID: NCT05982899

Last Updated: 2023-08-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

412 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-01

Study Completion Date

2023-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To explore the predictive factors of frailty trajectories and develop a web-based nomogram among gastric cancer survivors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aims of this study are to explore the predictive factors of frailty trajectories in gastric cancer patients more comprehensively based on the health ecology theory and to construct a clinically convenient web-based prediction calculator, so as to screen high-risk frailty elderly gastric cancer patients at an early stage in clinical practice, and thus to implement early interventions to improve the prognosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosed with gastric cancer by endoscopy or pathology;
* age ≥60 years old;
* radical gastrectomy was proposed;
* be able to communicate simply in writing and verbally.

Exclusion Criteria

* combined with other sites of malignant tumors;
* combined with severe heart, liver, lung, and renal insufficiency;
* recent using hormones, immunosuppressants;
* with physical disabilities.
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nanjing Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xueyi Miao

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xueyi Miao

Nanjing, Jiangsu, China

Site Status

Nanjing medical university

Nanjing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Guo Y, Miao X, Chen Y, Ding L, Zhao K, Xu T, Chen L, Xu X, Xu Q. Hypothetical Interventions on Frailty Heterogeneous Trajectories of Older Patients with Gastric Cancer Using Parametric G-Formula. Ann Surg Oncol. 2025 Oct;32(10):7634-7643. doi: 10.1245/s10434-025-18026-w. Epub 2025 Aug 9.

Reference Type DERIVED
PMID: 40783664 (View on PubMed)

Miao X, Guo Y, Ding L, Xu X, Zhao K, Zhu H, Chen L, Chen Y, Zhu S, Xu Q. A dynamic online nomogram for predicting the heterogeneity trajectories of frailty among elderly gastric cancer survivors. Int J Nurs Stud. 2024 May;153:104716. doi: 10.1016/j.ijnurstu.2024.104716. Epub 2024 Feb 13.

Reference Type DERIVED
PMID: 38412776 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-273

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.